CI_with has_Ingredient has_MoA has_PE may_prevent drug associated with AE in adult used to treat disease Drug Hypersensitivity [Disease/Finding] Graft vs Host Disease [Disease/Finding] Sirolimus [Chemical/Ingredient] Cellular Growth Phase Arrest [PE] Cellular Synthetic Phase Arrest [PE] Decreased T Lymphocyte Production [PE] Unknown Cellular or Molecular Interaction [MoA] S [Preparations] SIROLIMUS http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3275b824-3f82-4151-2ab2-0036a9ba0acc&type=display SIROLIMUS 4021176 W36ZG6FT64 <VANDF_Record>50.6^3589^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3589</VA_IEN> C19906 <VANDF_Record>50.416^3848^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3848</VA_IEN> Active 35302 C0072980 N0000148624 Ingredient Sirolimus lymphangioleiomyomatosis acne AE nasopharyngitis AE infection AE myalgia AE headache AE dizziness AE edema limbs AE abdominal pain AE chest pain AE nausea AE stomatitis AE diarrhea AE hypercholesteremia AE